Dr. Philip McMillan,  John McMillan

In November of 2023, Barry Young, a senior database administrator at New Zealand’s Te Whatu Ora health department, walked away from his career. He released vaccination and mortality records publicly after sharing them with his superiors on the same day, alleging clusters of unexplained deaths in the data he managed. He was arrested, bailed out, and still faces a court case. Whether his statistical analysis was sound, whether his disclosure cleared the legal bar of whistleblowing, whether he should have given his bosses more time, those are matters for a judge. The larger question sits outside the courtroom. Did New Zealand’s public health authorities fail the world by declining to carefully investigate what he had flagged?

That is the question raised in a recent commentary by Dr. Philip McMillan, a British researcher and clinician. It is not really a question about Young as a person, or about whether vaccines worked broadly across populations. It is a narrower, sharper question about scientific opportunity, and about what gets done with it.

Why New Zealand was a once-in-a-pandemic cohort

To grasp what was lost requires grasping what was uniquely possible. New Zealand’s geography and its early lockdown produced a population that almost no other country could offer to researchers. Through the alpha, beta, gamma, and delta waves that battered the rest of the world, the island remained relatively closed. Most New Zealanders received their first COVID-19 vaccinations before encountering the virus at all. They were, in epidemiological terms, infection-naive at the moment of vaccination.

That sequence matters. In nearly every other country, prior infection, prior vaccination, and ongoing transmission overlapped messily, blurring any signal a careful study might try to extract. In New Zealand, for a window of time, the variables could be cleanly separated. A clean cohort. A clean question. What happens to a vaccine-naive, infection-naive population when it meets the virus after vaccination?

The questions that went unasked

When Young’s data became public, officials examined his analysis broadly across the whole population and announced that no signal was visible. That was the wrong unit of analysis. “If you don’t want something to be done, it’s not going to happen,” Dr. McMillan said, framing what followed as a failure of will rather than a failure of evidence.

A serious investigation would have stratified the data into clinically meaningful windows. Day zero to seven after the first dose. Day seven to fourteen. Day fourteen to twenty-one. Then the same again after the second dose. The same across age brackets. The same across care-home residency and other high-risk groups. Broad population-level analysis dilutes any signal that lives inside a smaller cohort. That is not opinion, it is basic epidemiology.

Other questions were also left hanging. What did the autopsies of vaccinated people who later died with COVID-19 actually show? Did some patients mount strong antibody responses and still die? If they did, what was the underlying pathology? Was it the same pathology seen in unvaccinated patients who died of the disease? These are the kinds of details that move medical knowledge forward. New Zealand had the records, the pathology, and the cohort to answer them.

Patient-level questions matter because populations are not uniform. Frail elderly residents in care homes do not respond to an infection in the same way as healthy adults in their thirties. A signal lurking inside a small, vulnerable subgroup can be entirely real and entirely invisible at the level of a national average. That is the whole point of stratified analysis. To skip it is not to disprove the concern. It is to refuse to look.

A warning the world received in 2012

Long before SARS-CoV-2 emerged, scientists tried to build vaccines against SARS-CoV-1, the original SARS coronavirus from the early 2000s. In animal studies published around 2012, those candidate vaccines did produce antibody responses and did reduce infection rates. They also produced something else, a lung immunopathology consistent with an autoimmune reaction. The authors of those studies called for caution in any future human application.

That history does not, on its own, prove anything about the safety profile of modern COVID-19 vaccines. In the framework of medical reasoning, it does something more specific. It raises the prior probability that a particular question deserves to be asked. “Did prior vaccination change the pathology on re-exposure to the virus? This was a global question, because it could have guided what we did,” he said. New Zealand sat, perhaps uniquely, in a position to test it through a clean clinical cohort. The answer never came.

The pattern of not wanting to know

A darker thread runs through this story. The argument is less about proving harm and more about documenting a pattern. A health bureaucracy that did not want to investigate. A public conversation reframed as conspiracy talk before the science could be done. A legal proceeding now reportedly treating mortality evidence as irrelevant to whether the disclosure itself was lawful. Whether the legal framing is precisely accurate or not, the structural point lands hard. Some questions become unaskable not because the evidence has been examined and dismissed, but because no one with access to the data is willing to look closely.

That is the uncomfortable part. Science, at its best, runs on the discipline of asking hard questions and producing answers that can be defended. Bayesian reasoning, the kind clinicians use intuitively when they update their thinking with each new test result, takes prior signals seriously and asks whether the next study, the next autopsy, might tip the probability one way or the other. A health system that refuses to update its priors is not doing science. It is doing public relations.

Why this still matters

Boosters continue. Vaccination programs continue. The questions raised by the New Zealand cohort have not become less relevant because the news cycle moved on. If a particular subset of patients was at elevated risk from a specific dose, batch, or interval, that information would matter for clinicians making future decisions. If certain antibody profiles, including a possible shift toward IgG4 dominance with repeated boosting, change how a vaccinated patient responds to re-exposure, that has direct implications for clinical care.

None of this is a claim that vaccination broadly caused harm. It is a claim that a discoverable question was not investigated when the data, the cohort, and the timing made investigation possible. The cost of that omission is not zero. The warning is plain: outcomes are happening, trajectories are continuing, and a decade from now the relevant questions may still be unanswered.

The Barry Young case will be settled by lawyers. The scientific case New Zealand was positioned to make is harder to recover. A clean, isolated, vaccine-naive cohort of that size and clarity does not come twice. The opportunity has already passed, and what should have followed it remains, for now, a question without an answer.